Appili Therapeutics Announces Alignment With The FDA On The Development Requirements For Its ATI-1801 Topical Antiparasitic Product NDA Submission NOTE: Appili On Apr. 2 Announced Agreement To Which Aditxt Would Acquire All Issued And Outstanding Shares
Portfolio Pulse from Benzinga Newsdesk
Appili Therapeutics has announced an agreement with the FDA on the development requirements for its ATI-1801 topical antiparasitic product NDA submission. Additionally, Appili has agreed to be acquired by Aditxt, which will acquire all issued and outstanding shares.
October 31, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aditxt is set to acquire all issued and outstanding shares of Appili Therapeutics, which could expand its portfolio and market presence.
The acquisition of Appili Therapeutics by Aditxt could enhance Aditxt's product offerings and market reach, likely having a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80